Table 2.

Changes in ²³NaMRI parameters after 3 months of treatment with empagliflozin or placebo

Parameters after 3 months	Empagliflozin, change from baseline	p value empagliflozin vs. baseline	Placebo, change from baseline	p value placebo vs. baseline	Between-group difference	p value empagliflozin vs. placebo
Skin sodium content (AU)	− 1.3 ± 3.5	0.013	0.6 ± 3.5	0.384	− 2.1 ± 0.9	0.022
Muscle sodium content (AU)	− 0.3 ± 2.9	0.448	− 0.9 ± 3.0	0.169	0.5 ± 0.8	0.536
Muscle sodium content, inversion recovery sequence (AU)	− 0.1 ± 2.1	0.751	− 0.8 ± 2.6	0.141	0.7 ± 0.6	0.250
Muscle water content (ms)	0.5 ± 5.4	0.516	− 0.3 ± 4.5	0.732	0.8 ± 1.3	0.517
Muscle fat content (AU)	0.2 ± 2.1	0.481	0.4 ± 2.4	0.490	0.3 ± 0.6	0.790
Tibial bone marrow sodium content (AU)	− 0.6 ± 1.4	0.013	0.1 ± 1.1	0.825	− 0.6 ± 0.4	0.074

Data are mean ± standard deviation

AU arbitrary units